300 studies found for:    Endometrial Cancer: Clinical Trials
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Active, not recruiting Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
Conditions: Recurrent Cervical Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Uterine Sarcoma;   Stage I Endometrial Carcinoma;   Stage I Uterine Sarcoma;   Stage IA Cervical Cancer;   Stage IB Cervical Cancer;   Stage II Endometrial Carcinoma;   Stage II Uterine Sarcoma;   Stage IIA Cervical Cancer;   Stage IIB Cervical Cancer;   Stage III Cervical Cancer;   Stage III Endometrial Carcinoma;   Stage III Uterine Sarcoma;   Stage IV Endometrial Carcinoma;   Stage IV Uterine Sarcoma;   Stage IVA Cervical Cancer;   Stage IVB Cervical Cancer
Interventions: Other: medical chart review;   Other: questionnaire administration
2 Recruiting Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Fallopian Cancer;   Peritoneal Cancer
Interventions: Biological: E39 peptide vaccine;   Other: Clinical tracking for disease progression/recurrence
3 Active, not recruiting A Phase II Trial of Adjuvant Radiotherapy Combined With Chemotherapy for Patients With High-risk Endometrial Cancer
Condition: Prosthesis Survival
Interventions: Radiation: radiotherapy;   Drug: Cisplatin;   Drug: Cisplatin and Doxorubicin and Cyclophosphamide;   Drug: Paclitaxel and Carboplatin
4 Completed Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery
Condition: Endometrial Cancer
Intervention: Radiation: radiation therapy
5 Recruiting Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients
Condition: Endometrial Cancer
Interventions: Procedure: Intensive/Low-Risk Treatment (IA G1; IA G2);   Procedure: Intensive/High-Risk Treatment (≥ IA G3);   Procedure: Minimalist/Low-Risk Treatment (IA G1; IA G2);   Procedure: Minimalist/High-Risk Treatment (≥ IA G3)
6 Recruiting Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Radiation: Radiation Therapy;   Drug: cisplatin;   Drug: carboplatin;   Drug: Paclitaxel
7 Recruiting Prospective Randomised Phase II Trial Evaluating Adjuvant Pelvic Radiotherapy Using Either IMRT or 3-Dimensional Planning for Endometrial Cancer. ICORG 09-06
Conditions: Endometrial Cancer;   Gastrointestinal Complications;   Radiation Toxicity;   Urinary Complications
Intervention: Radiation: 45 Gy/25 fractions
8 Completed Clinical Trial of Ridaforolimus Compared to Progestin or Chemotherapy for Advanced Endometrial Carcinoma (MK-8669-007 AM6)
Condition: Endometrial Cancer
Interventions: Drug: ridaforolimus;   Drug: medroxyprogesterone acetate tablets OR megestrol acetate;   Drug: chemotherapy
9 Completed Trial of Vascular Endothelial Growth Factor (VEGF), Bevacizumab, in Combination With Cytotoxic Chemotherapy for Endometrial Cancer
Condition: Endometrial Carcinoma
Intervention: Drug: carboplatin, paclitaxel, and bevacizumab
10 Completed Surgery With or Without Lymphadenectomy and Radiation Therapy in Treating Patients With Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Procedure: adjuvant therapy;   Procedure: conventional surgery;   Radiation: brachytherapy;   Radiation: radiation therapy
11 Completed Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus
Conditions: Endometrial Cancer;   Sarcoma
Interventions: Procedure: conventional surgery;   Procedure: laparoscopic surgery
12 Recruiting Carboplatin-Paclitaxel ± Bevacizumab in Advanced (Stage III-IV) or Recurrent Endometrial Cancer
Condition: Stage III-IV or Recurrent Endometrial Cancer
Interventions: Drug: Bevacizumab;   Drug: Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
13 Completed Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma;   Stage IIIA Endometrial Carcinoma;   Stage IIIB Endometrial Carcinoma;   Stage IIIC Endometrial Carcinoma;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma
Interventions: Drug: temsirolimus;   Other: laboratory biomarker analysis
14 Terminated Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
Conditions: Uterine Cervical Cancer;   Endometrial Cancer
Intervention: Drug: Zalypsis ( PM00104)
15 Active, not recruiting Temsirolimus With or Without Megestrol and Tamoxifen in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer
Conditions: Recurrent Endometrial Carcinoma;   Stage III Endometrial Carcinoma;   Stage IV Endometrial Carcinoma
Interventions: Drug: megestrol acetate;   Drug: tamoxifen citrate;   Drug: temsirolimus;   Other: laboratory biomarker analysis
16 Unknown  External-Beam Radiation Therapy or Implant Radiation Therapy Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage I Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Other: clinical observation;   Procedure: adjuvant therapy;   Radiation: brachytherapy;   Radiation: radiation therapy
17 Completed POEM STUDY: A Phase IIa Trial in Endometrial Carcinoma With Temsirolimus
Conditions: Carcinoma, Endometrioid;   mTOR Protein
Intervention: Drug: Temsirolimus
18 Active, not recruiting PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent or Advanced Endometrial Cancer
Condition: Endometrial Cancer
Intervention: Drug: MK-2206
19 Unknown  Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
Conditions: Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions: Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
20 Completed Gefitinib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Condition: Recurrent Endometrial Carcinoma
Interventions: Drug: gefitinib;   Other: laboratory biomarker analysis

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years